CryoLife remains bullish over FDA warning
This article was originally published in Clinica
Executive Summary
US tissue implants company CryoLife, which last month was issued with a warning letter following an FDA inspection in March and April, maintains that the whole affair, while unwanted, will be able to yield some positives. Vice-president of corporate communications Roy Vogeltanz told Clinica that the public's understanding of the FDA system will have improved in the wake of the inspections (see No Clinica 1013, p 15).